MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319918 | Name: Ronacaleret HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ronacaleret, also known as SB751689, is an orally-active calcium-sensing receptor (CaSR) antagonist that has the potential for therapeutic utility in the stimulation of PTH release, notably as a bone anabolic agent comparable to recombinant human PTH(1-34) (rhPTH(1-34)). Administration of ronacaleret led to lower peak levels of PTH than were observed with rhPTH(1-34), however, greater total PTH exposure was observed.

Chemical Structure

Ronacaleret HCl
Ronacaleret HCl
CAS#702686-96-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 319918

Name: Ronacaleret HCl

CAS#: 702686-96-2 (HCl)

Chemical Formula: C25H32ClF2NO4

Exact Mass:

Molecular Weight: 483.98

Elemental Analysis: C, 62.04; H, 6.66; Cl, 7.32; F, 7.85; N, 2.89; O, 13.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
753449-67-1 (free base) 702686-96-2 (HCl)
Synonym
SB751689; SB-751689; SB 751689; SB751689A; SB-751689A; SB 751689A; SB751689-A; Ronacaleret HCl.
IUPAC/Chemical Name
(R)-3-(3-(3-((1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl)amino)-2-hydroxypropoxy)-4,5-difluorophenyl)propanoic acid hydrochloride
InChi Key
BQGSCEAKPBWIDI-VEIFNGETSA-N
InChi Code
InChI=1S/C25H31F2NO4.ClH/c1-25(2,13-17-9-18-5-3-4-6-19(18)10-17)28-14-20(29)15-32-22-12-16(7-8-23(30)31)11-21(26)24(22)27;/h3-6,11-12,17,20,28-29H,7-10,13-15H2,1-2H3,(H,30,31);1H/t20-;/m1./s1
SMILES Code
O=C(O)CCC1=CC(F)=C(F)C(OC[C@H](O)CNC(C)(C)CC2CC3=C(C=CC=C3)C2)=C1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 483.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Takenaka T, Inoue T, Miyazaki T, Nishiyama A, Ishii N, Hayashi M, Suzuki H. Antialbuminuric actions of calcilytics in the remnant kidney. Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F216-26. doi: 10.1152/ajprenal.00003.2015. Epub 2015 May 27. PubMed PMID: 26017971. 2: Vogt FG, Williams GR, Strohmeier M, Johnson MN, Copley RC. Solid-state NMR analysis of a complex crystalline phase of ronacaleret hydrochloride. J Phys Chem B. 2014 Aug 28;118(34):10266-84. doi: 10.1021/jp505061j. Epub 2014 Aug 18. PubMed PMID: 25133518. 3: Fitzpatrick LA, Wooddell M, Dabrowski CE, Cicconetti G, Gordon DN. Bone mineral density changes following discontinuation of ronacaleret treatment: off-treatment extension of a randomized, dose-finding phase II trial. Bone. 2014 Oct;67:104-8. doi: 10.1016/j.bone.2014.04.024. Epub 2014 May 2. PubMed PMID: 24794093. 4: Filopanti M, Corbetta S, Barbieri AM, Spada A. Pharmacology of the calcium sensing receptor. Clin Cases Miner Bone Metab. 2013 Sep;10(3):162-5. Review. PubMed PMID: 24554924; PubMed Central PMCID: PMC3917576. 5: Caltabiano S, Dollery CT, Hossain M, Kurtinecz MT, Desjardins JP, Favus MJ, Kumar R, Fitzpatrick LA. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. Bone. 2013 Sep;56(1):154-62. doi: 10.1016/j.bone.2013.05.021. Epub 2013 Jun 10. PubMed PMID: 23756230. 6: Endo I, Matsumoto T. [Update and perspectives of anabolic therapies for osteoporosis]. Clin Calcium. 2012 Mar;22(3):327-33. doi: CliCa1203327333. Review. Japanese. PubMed PMID: 22370299. 7: Diaz R. Bone: Ronacaleret in osteoporosis. Nat Rev Endocrinol. 2011 Nov 29;8(2):67. doi: 10.1038/nrendo.2011.212. PubMed PMID: 22124441. 8: Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Fuerst T, Engelke K, Genant HK. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2012 Feb;27(2):255-62. doi: 10.1002/jbmr.554. PubMed PMID: 22052452. 9: Atchison DK, Harding P, Beierwaltes WH. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension. 2011 Oct;58(4):604-10. doi: 10.1161/HYPERTENSIONAHA.111.172890. Epub 2011 Aug 8. PubMed PMID: 21825222; PubMed Central PMCID: PMC3174336. 10: Fitzpatrick LA, Smith PL, McBride TA, Fries MA, Hossain M, Dabrowski CE, Gordon DN. Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial. Bone. 2011 Oct;49(4):845-52. doi: 10.1016/j.bone.2011.06.017. Epub 2011 Jun 30. PubMed PMID: 21742071. 11: Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG 3rd, Bilezikian JP. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2011 Aug;96(8):2441-9. doi: 10.1210/jc.2010-2855. Epub 2011 May 18. PubMed PMID: 21593114. 12: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346. 13: Balan G, Bauman J, Bhattacharya S, Castrodad M, Healy DR, Herr M, Humphries P, Jennings S, Kalgutkar AS, Kapinos B, Khot V, Lazarra K, Li M, Li Y, Neagu C, Oliver R, Piotrowski DW, Price D, Qi H, Simmons HA, Southers J, Wei L, Zhang Y, Paralkar VM. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3328-32. doi: 10.1016/j.bmcl.2009.04.044. Epub 2009 Apr 18. PubMed PMID: 19442519. (last updated: 4/20/2016).